Does hormone replacement therapy (HRT) influence breast and ovarian cancer risk of non-diseased BRCA1/2-pV carriers without risk-reducing salpingo-oophorectomy (RRSO)? This evidence concerns the gene BRCA1 and ovarian carcinoma.